TICKERNERD
Menu
FRNMFRNMHealthcare · Diagnostics & Research

FRNM Stock Forecast: Freenome, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$16
+1.97% on the day

The 5 Wall Street analysts covering Freenome, Inc. hold a median 12-month price target of $17 — +6.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 23 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7B
Ticker Nerd rank
32 / 100
Median analyst target
$17
Analysts covering
5
Revenue$0.0
Operating income−$941K
Net income−$115K
Free cash flow−$130K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
+16.2%
YTD
+22.9%
1Y
+51.0%
From 52W high
−6.4%
From 52W low
+60.3%
$10
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FRNM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Freenome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
85
Issuance
58
Volatility
51
Value
45
Accruals
45
Size
37
Revisions
35
Quality
34
Growth
18

Momentum (85): The shares have been drifting up relative to others.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FRNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FRNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20$22Oct 25Jan 26Apr 26Jul 26FRNMHigh $21Median $17Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $17Median $17High $21

The green dot is the last close — the median target sits +6.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026GuggenheimInitiatesBuy$21
18 Aug 2026TD CowenInitiatesBuy$17
17 Aug 2026BTIGInitiatesBuy$17
17 Aug 2026JefferiesInitiatesBuy$17
14 Aug 2026Leerink PartnersInitiatesOutperform$18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FRNM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FRNM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, Freenome, Inc. returned +51.0% against +17.3% for the S&P 500, dividends included.

FRNM vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140150Oct 25Jan 26Apr 26Jul 26FRNMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FRNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Freenome, Inc. (FRNM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
593.5×

Cheaper than 1% of US stocks

Price / sales
47.6×

Cheaper than 6% of US stocks

Price / book
1.7×

Cheaper than 50% of US stocks

EV / EBITDA
−15.8×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
106.5%

Higher than 93% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−2867.5%

Higher than 4% of US stocks

Net margin
93.6%

Higher than 99% of US stocks

Returns & dividend
Return on equity
17.4%

Higher than 78% of US stocks

Return on assets
−43.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Freenome, Inc. (FRNM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Freenome, Inc. has a market value of $1.7B and an enterprise value of $3.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter grew 106.5% year on year.

  • Net income over the same four quarters: −$763K.

  • Free cash flow in the twelve months to 30 June 2026: −$907K.

  • Shares outstanding: 107.4M.

  • Trailing P/E: 593.5×; forward P/E: −6.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Freenome, Inc. employs 375 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

FRNM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
FRNMFreenome, Inc.$1.7B
32
PSNLPersonalis, Inc.$1.7B
42
OPKOPKO Health, Inc.$1.3B
82
NEONeoGenomics, Inc.$2.4B
77
WGSGeneDx Holdings Corp.$2.4B
46
CDNACareDx, Inc.$2.8B
99
CSTLCastle Biosciences, Inc.$1.0B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Freenome, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FRNM news & analysis

Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition

Seeking Alpha · 22 Sept 2026positive

Freenome's FDA-approved SimpleScreen CRC blood-based colorectal screening test has been out-licensed to Abbott, targeting a roughly 50 million patient total addressable market in the unscreened colorectal space. The deal includes up to $700M in milestone payments and 10% royalties, backed by a $410M cash reserve, with the upcoming PROACT LUNG study cited as a potential catalyst for its multiomics platform.

Why it matters — FRNM watchers would care because the Abbott licensing deal and cash position position Freenome to access the large unscreened colorectal cancer market, while the PROACT LUNG study could validate its platform across additional indications.

FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test

GlobeNewsWire · 12 Aug 2026positive

Freenome announced that the U.S. FDA granted Breakthrough Device Designation to SimpleScreen™ Lung, its investigational blood-based lung cancer screening test. The designation applies to the company's early cancer detection product.

Why it matters — Breakthrough Device Designation could facilitate a faster development and review path for Freenome's lung cancer screening test, potentially advancing its pipeline toward the market.

FDA approves Freenome's blood test for colorectal cancer screening

Reuters · 27 July 2026positive

The FDA approved Freenome's blood-based colorectal cancer screening test for older adults, with partner Abbott set to launch it in the U.S. this fall.

Why it matters — This FDA approval marks a key regulatory milestone for Freenome's lead product, enabling commercial launch through its partnership with Abbott.

FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

GlobeNewsWire · 27 July 2026positive

The FDA approved Freenome's SimpleScreen CRC blood-based colorectal cancer screening test, and Abbott will commercialize it in the United States. Medicare coverage and American Cancer Society guidance support broader access to the test, which aims to expand screening options for millions of Americans overdue for screening.

Why it matters — This FDA approval and commercialization partnership with Abbott mark a major regulatory and strategic milestone for Freenome's lead product candidate.

FAQ

Frequently asked questions about FRNM stock

What is the FRNM stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Freenome, Inc. have a median 12-month price target of $17, with estimates ranging from $17 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FRNM stock a buy right now?

Of the 5 analysts covering Freenome, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Freenome, Inc. 32 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FRNM?

As at 23 Sept 2026, Freenome, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (85 of 100).

Will FRNM stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +6.2% from the last close, and Ticker Nerd's factor model ranks Freenome, Inc. 32 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FRNM stock forecast for 2030?

No analyst covering Freenome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FRNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $21 over the next 12 months.

How has FRNM stock performed over the past year?

Freenome, Inc. returned +51.0% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Freenome, Inc. do?

Freenome Inc. is a biotechnology company focused on early cancer detection through blood-based screening tests.

What is the latest news on FRNM?

The most recent item we track (Seeking Alpha, 22 Sept 2026): "Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition". Freenome's FDA-approved SimpleScreen CRC blood-based colorectal screening test has been out-licensed to Abbott, targeting a roughly 50 million patient total addressable market in the unscreened colorectal space. The deal includes up to $700M in milestone payments and 10% royalties, backed by a $410M cash reserve, with the upcoming PROACT LUNG study cited as a potential catalyst for its multiomics platform.

Company

About Freenome, Inc.

Freenome Inc. is a biotechnology company focused on early cancer detection through blood-based screening tests. The company develops a multiomics platform that combines molecular biology, artificial intelligence, and machine learning to analyze subtle biological signals associated with cancer. Its current product work centers on noninvasive screening tools for colorectal cancer, along with broader blood tests aimed at detecting multiple cancers and other diseases at earlier, more treatable stages. Freenome’s technology is designed to support clinical screening programs and improve access to cancer detection through a standard blood draw, making it relevant to diagnostics, preventive care, and precision medicine. Headquartered in Brisbane, California, Freenome operates at the intersection of biotechnology, data science, and medical diagnostics, with a focus on simplifying how cancer is identified in routine healthcare settings.

CEO Mr. Aaron Elliott Ph.D. · 375 employees · United States · https://www.freenome.com